Bvf Partners LP Il Insider Profile
662 Followers
Bvf Partners LP Il, Director, See Remarks and Footnotes at Kymera Therapeutics, holds 0.00 shares in XOMA Royalty Corporation (Ticker: XOMA), holds 318.91K shares in Kymera Therapeutics (Ticker: KYMR), holds 15.94M shares in MoonLake Immunotherapeutics (Ticker: MLTX).
Bvf Partners LP Il Kymera Therapeutics (KYMR)Director, See Remarks and Footnotes
Kymera Therapeutics (KYMR)
Director, See Remarks and Footnotes
Ranked #38 out of 108,921 Corporate Insiders
Profitable Transactions
93 out of 145 Profitable Transactions
Average Return
+51.30%
Average return per transaction
Time Frame
Compare to
Insider Holdings
A breakdown of Bvf Partners LP Il's holdings
Insider Roles
Roles that Bvf Partners LP Il holds in companies
Most Profitable Insider Trade
Stock:
Five Prime Therapeutics
(FPRX)
(FPRX)
Rating:Informative Buy
Date:Nov 26, 2019 - Nov 26, 2020
Return:+467.90%
The most profitable trade made by Bvf Partners LP Il
Bvf Partners LP Il's Trading History
Kymera Therapeutics
Jun 26, 2026
Director, See Remarks and Footnotes
Informative Sell
173.67M
$36.66M
Olema Pharmaceuticals
Jan 14, 2025
Director, See Explanation of Responses
Uninformative Sell
―
$52.20M
Eledon Pharmaceuticals
May 13, 2024
Ten Percent Owner
Uninformative Buy
―
$17.28M
CytomX Therapeutics
―
See Explanation of Responses
―
$17.99M
Rain Oncology
Jan 29, 2024
―
Uninformative Sell
―
$0.00
Repare Therapeutics
Jan 30, 2026
―
Uninformative Sell
―
$0.00
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
―
$1.32M
Third Harmonic Bio, Inc.
Oct 31, 2024
―
Informative Sell
14.30M
$950.60K
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
―
$200.02M
MoonLake Immunotherapeutics
Apr 02, 2026
Director, Ten Percent Owner
Informative Sell
62.96M
$199.43M
POINT Biopharma Global
Dec 20, 2023
―
Informative Sell
213.66M
$0.00
4D Molecular Therapeutics
Nov 13, 2024
See Explanation of Responses
Uninformative Sell
―
$1.16M
Allakos
May 19, 2025
―
Uninformative Sell
―
$0.00
ESSA Pharma
Oct 14, 2025
―
Uninformative Sell
―
$0.00
CTI BioPharma
Jun 28, 2023
―
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
―
$3.49M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
―
XOMA Royalty Corporation
Jul 16, 2026
―
Uninformative Sell
―
$0.00
Crescent Biopharma
Jun 17, 2025
Ten Percent Owner
Uninformative Buy
―
$1.21M
Concert Pharma
Jun 12, 2019
―
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
―
$1.55M
Immune Design
Dec 04, 2018
―
Informative Sell
1.65M
$2.17M
Palvella Therapeutics
Dec 17, 2024
See Explanation of Responses
Uninformative Buy
―
$5.85M
Five Prime Therapeutics
Nov 13, 2020
―
Informative Sell
149.20M
$3.09M
Calithera Bio
May 26, 2020
―
Informative Sell
13.70M
$12.01K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$521.26M
Merus
Oct 08, 2021
―
Informative Sell
31.22M
$20.95M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$8.76M
Principia Biopharma
―
―
―
―
ChemoCentryx
Nov 05, 2015
―
Uninformative Sell
―
$177.51M
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$16.19M
Cascadian Therapeutics
Dec 22, 2015
―
Informative Buy
―
$207.39M
Dynavax
Sep 11, 2009
―
Informative Sell
3.35M
$265.29M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.41B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.83B
Epirus Biopharma
Dec 24, 2009
―
Informative Sell
2.54M
$13.66M
Array Biopharma
Jul 10, 2014
―
Uninformative Sell
2.25M
$596.76M
Amag Pharmaceuticals
―
―
―
$14.15M
Arqule
Jun 01, 2018
―
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$359.43M
Tobira Therapeutics
Mar 25, 2014
―
Uninformative Sell
―
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$6.73M
Repros
―
―
―
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$37.03M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$29.44M
Astex Pharmaceuticals
―
―
―
―
Medicinova
―
Ten Percent Owner
―
$0.00
NPS Pharma
―
―
―
―
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock
You May Also Like
Bvf Partners LP Il insider profile FAQ
What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 64%.
What is the average return per transaction made by Bvf Partners LP Il?
The average return per transaction made by Bvf Partners LP Il is 51.30%.
What stocks does Bvf Partners LP Il hold?
Bvf Partners LP Il holds: KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, PNT, FDMT, ALLK, EPIX, CTIC, XENE, INFIQ, XOMA, CBIO, CNCE, SNDX, IMDZ, PVLA, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, ~CCXI, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTN, ~ASTX, MNOV, NPSP stocks.
What was Bvf Partners LP Il’s latest transaction?
Bvf Partners LP Il latest transaction was an Uninformative Sell of ―.
What was Bvf Partners LP Il's most profitable transaction?
Bvf Partners LP Il’s most profitable transaction was an Informative Buy of FPRX stock on November 26, 2019. The return on the trade was 467.90%.
What is Bvf Partners LP Il's role in Kymera Therapeutics?
Bvf Partners LP Il's role in Kymera Therapeutics is Director, See Remarks and Footnotes.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.